GET DAILY SIGNALSKORU Medical Systems (KRMD) Analyst Targets Suggest Significant Upside Potential
Key Takeaways
- The central stock price target of $6.25 is the arithmetic mean of four current, verifiable analyst price targets, ranging from $5.00 to $8.00.
- With shares trading near $3.23, reaching $6.25 would require a gain of roughly 94%, a very large move.
- Four firms cover the stock closely: Piper Sandler ($5, Hold), Canaccord Genuity ($6, Buy), Craig-Hallum ($6, Buy), and B. Riley Securities ($8, Buy).
- The strongest support comes from accelerating revenue growth and progress toward profitability, while the biggest risk is a persistent, multi-month downtrend toward the 52-week low.
- Analyst views diverge meaningfully — the $5-to-$8 spread is roughly 60% wide — reflecting genuine disagreement about execution risk.
- For more context on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages on Tickeron.
- To see how automated systems are reading changing market conditions across thousands of stocks, explore Trending AI Robots.
Analyst Price Targets and Consensus View
KORU Medical Systems, Inc. (KRMD) is a Nasdaq-listed medical device company that designs and commercializes subcutaneous infusion systems used in large-volume drug delivery and contract manufacturing. Its current analyst coverage centers on four recently updated targets: Piper Sandler reiterated a Hold with a $5 target, Canaccord Genuity and Craig-Hallum both reiterated Buy ratings at $6, and B. Riley Securities reiterated a Buy at $8. The arithmetic mean of these four figures is $6.25, with a range of $5.00 to $8.00.
The dispersion is notable. The most cautious view (Piper Sandler) still sits about 55% above the current price, while the highest target implies roughly 148% upside. In a sign of tempered enthusiasm, Craig-Hallum trimmed its target from $7 to $6 in early August 2026 even while maintaining its Buy rating, whereas B. Riley raised its target to $8 in March. This mix of a reduced target at one firm and a raised target at another underscores that analysts are not in lockstep about the pace of the company's recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent price near $3.23, KRMD sits toward the lower end of its 52-week range of roughly $2.86 to $6.61, with a market capitalization near $149 million. Moving to $6.25 from $3.23 requires an advance of about 94%, which is a very large move for a small-cap name over any reasonable horizon. The path would likely depend on sustaining revenue momentum, converting that growth into consistent profitability, and rebuilding investor confidence after a decline of roughly 49% from the start of 2026.
Fundamentals show encouraging signs: trailing twelve-month revenue has grown more than 20% year over year to roughly $45 million, and the company has been narrowing losses toward breakeven, with recent quarters showing improved operating performance. However, the stock trades on negative EPS (earnings per share), meaning it cannot yet be valued on a conventional P/E (price-to-earnings) basis, which adds uncertainty to any price forecast.
What Could Support a Move Toward the Target
Several factors underpin the bullish analyst price targets. Revenue has grown at a double-digit pace, driven by both domestic and international core product demand plus pharma-services activity. Gross margins remain healthy, and the company has been steadily reducing operating losses, suggesting an improving path toward profitability. Continued execution on this trajectory — alongside new drug-pump partnerships, regulatory clearances, or larger contract-manufacturing deals — could give analysts reason to hold or raise their targets.
Valuation also plays a role. The bullish firms argue that shares, trading near multi-year lows after a steep sell-off, may over-discount the company's growth prospects. If revenue growth persists and losses keep narrowing, a re-rating toward the higher end of the analyst range becomes a more plausible scenario.
What Could Prevent the Target From Being Reached
The principal risk is that the recent stock decline reflects genuine skepticism rather than mispricing. The shares sit below both their 50-day and 200-day moving averages, signaling persistent selling pressure. As a small-cap with a limited product line concentrated in subcutaneous infusion technology, KORU Medical is exposed to customer concentration, reimbursement and regulatory changes, and competition from larger medical-device players.
Any slowdown in revenue growth, a guidance cut, or a return to wider operating losses could undercut the higher analyst targets. The gap between the $5 and $8 targets also shows that analysts themselves disagree on how quickly — or whether — the company can deliver sustained profitability.
Technical Levels and Market Structure
Technically, the picture is challenging. The 52-week low near $2.86 stands as the key support level to hold, while the psychological $5.00 level and the prior highs near $6.60 represent major resistance zones on the way toward the $6.25 target. The stock trades below its long-term moving averages, and any durable recovery would first require reclaiming those averages before a sustained advance toward the analyst targets becomes credible. From what I see, monitoring these levels closely helps clarify whether momentum is shifting.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary in their methodology and timing. Upcoming items most relevant to the target include the company's quarterly earnings releases and guidance, any changes to analyst ratings or targets, new product or partnership announcements, and developments in the broader medical-device and drug-delivery sector. Investors should also watch whether the company can string together consecutive quarters of revenue growth with shrinking losses. I’m watching this closely as earnings approach.
Using Tickeron’s AI Daily Buy/Sell Signals
In my analysis of names like this, Tickeron’s AI Daily Buy/Sell Signals provide a useful way to track shifting conditions across thousands of stocks. The tool generates Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis, which can help spot momentum changes in a volatile small-cap more efficiently than manual checks alone. It has become a regular part of how I monitor positions and identify potential opportunities as market dynamics evolve.
Final Assessment
Can KORU Medical Systems (KRMD) stock reach $6.25? The target, an arithmetic mean of four current analyst targets spanning $5 to $8, implies a very large gain of about 94% from recent levels near $3.23. The bull case rests on sustained double-digit revenue growth and a narrowing path to profitability, while the bear case centers on persistent technical weakness, negative earnings, and a small-cap's concentration risks. With analysts themselves split across a wide range, the question ultimately hinges on execution: whether the company can keep growing revenue and turn that growth into consistent profits. Investors should watch earnings, guidance, and analyst revisions rather than treating the $6.25 average as a certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for KRMD shows an upward move is likely
KRMD's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 167 similar instances where the Aroon Indicator showed a similar pattern. In 144 of the 167 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 59 cases where KRMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for KRMD just turned positive on October 12, 2026. Looking at past instances where KRMD's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
KRMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRMD crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRMD advanced for three days, in 178 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRMD as a result. In 96 of 112 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
KRMD broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.904) is normal, around the industry mean (4.964). KRMD has a moderately low P/E Ratio (-77.250) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.770) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.292) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. KRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the design, manufacture, and market of proprietary medical devices
Industry PharmaceuticalsOther
Advertisement